Почетна › Кардиоваскуларне болести › Оклахома
Kliničke studije za Кардиоваскуларне болести u državi Оклахома
13 studija za Кардиоваскуларне болести traži učesnike na lokacijama u državi Оклахома.
Gradovi u državi Оклахома
Zvanični tekst studije (na engleskom)
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
- Clinical Trial Site, Edmond
- Clinical Trial Site, Moore
- Clinical Trial Site, Norman
- и још 1
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07181109EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- Tekton Research Oklahoma City, Oklahoma City
- South Oklahoma Heart Research Group, Oklahoma City
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07064473INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery
- Saint Francis Hospital - Tulsa, Tulsa
Тражи се учесник
Узраст од 18 до 80 · Оба пола · Ажурирано 12. 11. 2026. · NCT06965504A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
- Oklahoma Heart Institute, Tulsa
Тражи се учесник
Узраст од 18 до 85 · Оба пола · Ажурирано 10. 11. 2026. · NCT07214376Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
- Integris Baptist Medical Center, Oklahoma City
- Oklahoma Heart Institute at Utica, Tulsa
- Saint Francis Hospital, Tulsa
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06526195Tricuspid Regurgitation Treatment With LAPLACE Transcatheter Tricuspid Valve Replacement System
- Oklahoma Heart Institute, Tulsa
Тражи се учесник
Узраст од 18 до 90 · Оба пола · Ажурирано 2. 11. 2026. · NCT07687485Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
- Integris Baptist Medical Center, Oklahoma City
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT03242642Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
- South Oklahoma Heart Research, LLC, Oklahoma City
Тражи се учесникФаза 4
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06909565A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
- Research Site, Oklahoma City
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 24. 8. 2026. · NCT07000357OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
- Alliance for Multispecialty Research, Norman
Тражи се учесникФаза 3
Узраст од 50 до 105 · Оба пола · Ажурирано 21. 8. 2026. · NCT07136012The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
- Oklahoma Heart Institute Hospital, Tulsa
- Saint Francis Hospital,, Tulsa
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 13. 4. 2026. · NCT03142152MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels
- University of Oklahoma Health Science Center, Oklahoma City
Тражи се учесник
Узраст од 18 до 80 · Оба пола · Ажурирано 11. 9. 2025. · NCT06271590MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
- Oklahoma University Health (OU Health), Oklahoma City
Тражи се учесник
Узраст од 18 до 110 · Оба пола · Ажурирано 25. 2. 2025. · NCT05908331Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.